# Erasca

> Clinical-stage oncology company developing therapies that shut down multiple cancer growth pathways simultaneously.

## Why it is interesting

Founded by Ignyta alum Jonathan Lim, Erasca raised one of 2020's largest biotech rounds ($200M Series B) to pursue multi-pathway cancer drugging beyond single-target bets, then listed on NASDAQ as ERAS in 2021.

## Profile

- **Stage:** public
- **Status:** public
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series B (Apr 2020): $200M co-led by ARCH Venture Partners (/fund/arch-venture-partners) and Cormorant Asset Management
- IPO (Jul 2021): Listed on NASDAQ as ERAS
- Thesis: multi-pathway oncology drugging targeting RAS/MAPK and related cancer signaling

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/erasca